Pagnotti Gabriel M, Styner Maya
Department of Biomedical Engineering, Stony Brook University , Stony Brook, NY , USA.
Department of Medicine, University of North Carolina , Chapel Hill, NC , USA.
Front Endocrinol (Lausanne). 2016 Jul 14;7:94. doi: 10.3389/fendo.2016.00094. eCollection 2016.
Despite association with low bone density and skeletal fractures, marrow adipose tissue (MAT) remains poorly understood. The marrow adipocyte originates from the mesenchymal stem cell (MSC) pool that also gives rise to osteoblasts, chondrocytes, and myocytes, among other cell types. To date, the presence of MAT has been attributed to preferential biasing of MSC into the adipocyte rather than osteoblast lineage, thus negatively impacting bone formation. Here, we focus on understanding the physiology of MAT in the setting of exercise, dietary interventions, and pharmacologic agents that alter fat metabolism. The beneficial effect of exercise on musculoskeletal strength is known: exercise induces bone formation, encourages growth of skeletally supportive tissues, inhibits bone resorption, and alters skeletal architecture through direct and indirect effects on a multiplicity of cells involved in skeletal adaptation. MAT is less well studied due to the lack of reproducible quantification techniques. In recent work, osmium-based 3D quantification shows a robust response of MAT to both dietary and exercise intervention in that MAT is elevated in response to high-fat diet and can be suppressed following daily exercise. Exercise-induced bone formation correlates with suppression of MAT, such that exercise effects might be due to either calorie expenditure from this depot or from mechanical biasing of MSC lineage away from fat and toward bone, or a combination thereof. Following treatment with the anti-diabetes drug rosiglitazone - a PPARγ-agonist known to increase MAT and fracture risk - mice demonstrate a fivefold higher femur MAT volume compared to the controls. In addition to preventing MAT accumulation in control mice, exercise intervention significantly lowers MAT accumulation in rosiglitazone-treated mice. Importantly, exercise induction of trabecular bone volume is unhindered by rosiglitazone. Thus, despite rosiglitazone augmentation of MAT, exercise significantly suppresses MAT volume and induces bone formation. That exercise can both suppress MAT volume and increase bone quantity, notwithstanding the skeletal harm induced by rosiglitazone, underscores exercise as a powerful regulator of bone remodeling, encouraging marrow stem cells toward the osteogenic lineage to fulfill an adaptive need for bone formation. Thus, exercise represents an effective strategy to mitigate the deleterious effects of overeating and iatrogenic etiologies on bone and fat.
尽管骨髓脂肪组织(MAT)与低骨密度和骨骼骨折有关,但其仍未被充分了解。骨髓脂肪细胞起源于间充质干细胞(MSC)池,该细胞池还可产生成骨细胞、软骨细胞和肌细胞等其他细胞类型。迄今为止,MAT的存在被归因于MSC优先偏向脂肪细胞而非成骨细胞谱系,从而对骨形成产生负面影响。在此,我们专注于了解在运动、饮食干预和改变脂肪代谢的药物作用下MAT的生理学。运动对肌肉骨骼强度的有益作用是已知的:运动可诱导骨形成,促进骨骼支持组织的生长,抑制骨吸收,并通过对参与骨骼适应的多种细胞的直接和间接作用改变骨骼结构。由于缺乏可重复的定量技术,对MAT的研究较少。在最近的研究中,基于锇的三维定量显示MAT对饮食和运动干预均有强烈反应,即高脂肪饮食会使MAT升高,而每日运动后MAT可被抑制。运动诱导的骨形成与MAT的抑制相关,因此运动的效果可能是由于该储存库的热量消耗,或者是MSC谱系从脂肪向骨的机械偏向,或两者兼而有之。用抗糖尿病药物罗格列酮治疗后——罗格列酮是一种已知会增加MAT和骨折风险的PPARγ激动剂——与对照组相比,小鼠股骨MAT体积高出五倍。除了防止对照小鼠中MAT的积累外,运动干预还能显著降低罗格列酮治疗小鼠中MAT的积累。重要的是,罗格列酮并不妨碍运动诱导的小梁骨体积增加。因此,尽管罗格列酮会增加MAT,但运动仍能显著抑制MAT体积并诱导骨形成。尽管罗格列酮会对骨骼造成损害,但运动既能抑制MAT体积又能增加骨量,这突出了运动作为骨重塑的有力调节因子的作用,促使骨髓干细胞向成骨谱系分化,以满足骨形成的适应性需求。因此,运动是减轻暴饮暴食和医源性病因对骨骼和脂肪的有害影响的有效策略。